Cox RA, Garcia-Palmieri MR. Cholesterol, Triglycerides, and Associated Lipoproteins. In: rd, Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations, https://www.ncbi.nlm.nih.gov/pubmed/21250192. Boston1990.
LIPIDS. In: Janson LW, Tischler ME. eds. The Big Picture: Medical Biochemistry 2018 New York, NY: McGraw-Hill. http://accessmedicine.mhmedical.com/content aspx?bookid=2355§ionid= 185844384. Accessed November 26, 2019.
Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext, https://www.ncbi.nlm.nih.gov/pubmed/26247089. South Dartmouth (MA)2018.
Authors/Task Force M, Guidelines ESCCfP, Societies ESCNC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014.
Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. http://dx.doi.org/10.1016/j.jacc.2016.11.042.
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528. http://dx.doi.org/10.1056/NEJMoa0902604.
Emerging Risk Factors C, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-423. http://dx.doi. org/10.1001/jama.2009.1063.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG.Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. http://dx.doi.org/10.1001/jama.2009.801.
Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers.2019;5(1):56. http://dx.doi. org/10.1038/s41572-019-0106-z.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. http://dx.doi.org/10.1016/j.jacc.2018.11.002.
Smith SC, Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline fromthe American Heart Association and American College of CardiologyFoundation. Circulation. 2011;124(22):2458-2473. http://dx.doi.org/10.1161/CIR.0b013e318235eb4d.
ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease,2019. Weblink:https://www.acc.org/latest-in-cardiology/ten-points-toremember/2019/03/… Accessed on 03/12/2019.
Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. https://www.ncbi.nlm.nih.gov/pubmed/25340243. London2014.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315- 2381. http://dx.doi.org/10.1093/eurheartj/ehw106.
Feingold K, Grunfeld C. Lipoprotein Apheresis. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext, https://www.ncbi.nlm.nih.gov/pubmed/28402616. South Dartmouth (MA)2017.
European Cardiovascular Disease Statistics. 2017th ed. European Heart Network; Brussels, Belgium: 2017. http://www.ehnheart.org/cvd-statistics.html.Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol.